

***Fig.1***





Transgenic mouse (MMTV-Wnt-1) spontaneous breast cancer

***Fig.2***





Transgenic mouse (MMTV-Wnt-1) spontaneous breast cancer

***Fig.3***





Transgenic mouse (MMTV-Wnt-1) spontaneous breast cancer

***Fig.4***





Mouse breast cancer 4T1 cell

***Fig.5***





Human breast cancer MDA-MB-231 cell

***Fig.6***





Human melanoma cell line SEKI

***Fig.7***





Human melanoma cell line SEKI

***Fig.8***





Human anaplastic thyroid cancer cell line HTC/C3

***Fig.9***





Human anaplastic thyroid cancer cell line HTC/C3

***Fig.10***





Human anaplastic thyroid cancer cell line HTC/C3

***Fig.11***





Human hepatocellular carcinoma line SNU398 cell

***Fig.12***





Human hepatocellular carcinoma line SNU398 cell

***Fig.13***





Human hepatocellular carcinoma line SNU398 cell

***Fig.14***





Human hepatocellular carcinoma line HepG2 cell

***Fig.15***




Human colorectal cancer line Colo-205 cell


***Fig.16***





Human renal cell carcinoma line A-498 cell

***Fig.17***


(a) Control group



(b) E7386 alone administration group



(c) Lenvatinib mesylate alone administration group




(d) E7386 and lenvatinib mesylate combined administration group




# *Fig.18*


(a) Control group



(b) E7386 alone administration group



(c) Lenvatinib mesylate alone administration group



(d) E7386 and lenvatinib mesylate combined administration group






***Fig.19***





Mouse breast cancer 4T1 cell

***Fig.20***





Mouse breast cancer 4T1 cell

***Fig.21***




Human hepatocellular carcinoma line HepG2 cell

***Fig.22***




Human hepatocellular carcinoma line HepG2 cell